Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
12.23
-0.95 (-7.21%)
Mar 31, 2025, 1:25 PM EDT - Market open
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Syndax Pharmaceuticals stock have an average target of 36.2, with a low estimate of 16 and a high estimate of 51. The average target predicts an increase of 195.99% from the current stock price of 12.23.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Syndax Pharmaceuticals stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $39 → $41 | Buy | Maintains | $39 → $41 | +235.24% | Mar 20, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $35 → $39 | Buy | Maintains | $35 → $39 | +218.89% | Mar 4, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $45 → $42 | Strong Buy | Maintains | $45 → $42 | +243.42% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $51 | Strong Buy | Reiterates | $51 | +317.01% | Mar 4, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $18 → $16 | Hold | Maintains | $18 → $16 | +30.83% | Jan 8, 2025 |
Financial Forecast
Revenue This Year
88.77M
from 23.68M
Increased by 274.86%
Revenue Next Year
204.58M
from 88.77M
Increased by 130.47%
EPS This Year
-3.91
from -3.72
EPS Next Year
-2.86
from -3.91
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 174.0M | 278.3M | 636.9M | ||
| Avg | 88.8M | 204.6M | 387.6M | ||
| Low | 45.7M | 128.9M | 224.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 634.9% | 213.6% | 211.3% | ||
| Avg | 274.9% | 130.5% | 89.5% | ||
| Low | 93.0% | 45.2% | 9.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.76 | -1.29 | -0.89 | ||
| Avg | -3.91 | -2.86 | -1.66 | ||
| Low | -4.56 | -3.49 | -2.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.